期刊文献+

黄芩汤论治吉非替尼不良反应探析 被引量:1

Application of Huangqin Decoction in Treating Gefitinib Side Effects
原文传递
导出
摘要 肺癌的基本病机为气机不利、津液布散失调,吉非替尼治疗肺癌效果良好,且对寒湿之肺腺癌、阳气不充之亚裔女性、无热毒之不吸烟者疗效更佳,可知吉非替尼中药性能为辛热,其治疗作用来自其辛热之性,不良反应也与辛热之性密切相关。吉非替尼不良反应泄泻、皮疹、皮肤瘙痒、脱屑的特点均表现为温邪伤及太阳少阳二经的症候,而黄芩汤针对的基本病机为太阳少阳合病,与吉非替尼一系列不良反应背后的病机相一致,基于此,可知以黄芩汤为主方能治疗吉非替尼不良反应。 The basic pathogenesis of cancer is disorder of qi movement and fluid. The gefitinib not only works well in the treatment of cancer, but also work better in following three aspects: lung adenocarcinoma with cold-dampness syndrome, Asian women with yang deficiency syndrome, Non-smoker with no heat-toxicity. So we learn from this fact that The gefitinib’s four nature of drugs is hot, the five flavours of The gefitinib is pungent, the curative effect and the side effects both come from Chinese herbal medicine property. We can attribute aolmost all of side effects to heat pathogen invading Taiyang and Shaoyang Channels. In Shanghan Lun, huangqin decoction is a model answer of concurrent disease of Taiyang and Shaoyang Channels. Based on this, we can draw a conclusion that huangqin decoction works well in treating gefitinib side effects.
作者 邓凌晨 王倩 严然 祝捷 由凤鸣 Deng Ling-chen;Wang Qian;Yan Ran;Zhu Jie;You Fing-ming(Affiliated hospital of Chengdu University of Traditional Chinese Medicine,Chengdu Sichuan 610075;Institute of oncology,Chengdu University of Traditional Chinese Medicine,Chengdu Sichuan 610075)
出处 《按摩与康复医学》 2021年第2期60-63,共4页 Chinese Manipulation and Rehabilitation Medicine
关键词 吉非替尼 黄芩汤 不良反应 肺腺癌 gefitinib huangqin decoction side effects lung adenocarcinoma
  • 相关文献

参考文献3

二级参考文献20

  • 1宋兴.陈潮祖教授“五脏宜通”论[J].成都中医学院学报,1993,16(4):1-4. 被引量:3
  • 2吴玉生,杨海燕.邓铁涛教授“痰瘀相关理论”在肿瘤疾病的临床应用[J].现代医院,2005,5(6):39-40. 被引量:19
  • 3王三虎.《金匮要略》与肿瘤[J].河南中医,2005,25(8):6-8. 被引量:9
  • 4林丽珠.周岱翰教授从痰辨治癌症经验介绍[J].新中医,2006,38(3):10-12. 被引量:22
  • 5宋兴.中医治癌问题反思[J].新中医,1997,29(1):28-30. 被引量:7
  • 6Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002,346(2) :92 -98.
  • 7Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo- naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J]. Ann Oncol, 2013,24( 1 ) : 54 - 59.
  • 8Serizawa M, Koh Y, Kenmotsu H, et al. Assessment of mu- tational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study [J]. Cancer, 2014,120(10) :1471 - 1481.
  • 9Schneider CP, Heigener D, Schott-von-Romer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study [ J]. J Thorac Oncol, 2008,3 ( 12 ) : 1446 - 1453.
  • 10Cohen MH, Williams GA, Sridhara R, et al. FDA Drug Ap-proval Summary : Gefitinib (ZD1839) (Iressa.()) Tablets [J]. Oncologist, 2003, 8(4) : 303 -306.

共引文献22

同被引文献28

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部